噻唑烷二酮类药物对骨骼的影响

In women,short-term clinical trials demonstrated substantial bone loss with thiazolidinedi-one. Pioglitazone and rosiglitazone are widely used to treat diabetes, and better knowledge of their skeletal effects is crucial to guide clinical decisions. The randomized trial provides that rosiglitazone causes bone loss. An imbalance in fracture rates was identified in a final review of adverse event reports in ADOPT trial. That may result from the loss of bone mass due to thiazolidinedione. Animal and in vitro studies suggest that activ-tion of PPARγ promotes adipegenesis at the expense of osteoblastogenesis, and therefore inhibit bone forma-tion and induce bone loss.

Effects of thiazolidinedione on the bone